Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XMT-1001 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| XMT-1001 | EXPERIMENTAL | XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m\^2, the next dose level is 30 mg/m\^2, followed by dose levels: 50 mg/m\^2, 80 mg/m\^2, 120 mg/m\^2, 150 mg/m\^2, and 190 mg/m\^2 until disease progressions or unacceptable side effects are experienced. |
| Name | Type | Description |
|---|---|---|
| XMT-1001 | DRUG | XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD. |
Inclusion Criteria: 1. At least 18 years old 2. Have histological or cytological documentation of one of the following: A. NSCLC with Stage IV disease according to the American Joint Cancer Commission TNM Staging (7th Edition) * Have received at least one prior chemotherapy regimen but no mo...
Top 20 of 84 competitors
XMT-1001 is an investigational small molecule being studied for the treatment of Small Cell Lung Cancer. It is in Phase 1 clinical development and has been evaluated in a completed trial that also included patients with Non-small Cell Lung Cancer.
XMT-1001 is being developed by Day One Biopharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol DAWN. The drug is currently in Phase 1 clinical development for oncology indications.
XMT-1001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under investigation for Small Cell Lung Cancer.
XMT-1001 has been studied in one completed Phase 1 clinical trial, identified as NCT00455052. This trial, titled "A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors," enrolled 30 participants in the United States and included patients with Small Cell Lung Cancer and Non-small Cell Lung Cancer.
XMT-1001 is a distinct investigational small molecule developed by Day One Biopharmaceuticals. No alternative names for this drug have been disclosed in the available clinical trial information.